Literature DB >> 35925269

[Cytopathology and molecular diagnostics of non-small cell lung cancer (NSCLC)].

Jana Fassunke1, Marianne Engels1, Sonja Meemboor1, Reinhard Buettner2.   

Abstract

Cytological specimens from endobronchial aspirates and pleural effusions are frequently used materials in the diagnostics of non-small cell lung cancer (NSCLC). In the same way as histological samples from endobronchial and transbronchial biopsy material or computed tomography (CT)-guided needle biopsies, cytological specimens are eminently suitable for molecular and immunohistological biomarker diagnostics of NSCLC, provided optimal techniques and clear diagnostic algorithms are employed. This article presents the typical processing techniques and a scheme for biomarker analytics and discusses an optimal approach for comprehensive diagnostics of NSCLC. When cytological specimens are processed and used in this way, the analytics are equivalent to those from histopathological specimens. For a detailed and advanced description of cytological and molecular techniques on cytological specimens the reader is referred to our own review articles.
© 2022. The Author(s).

Entities:  

Keywords:  Biomarker analytics; Biopsy, needle; Cell sampling; Cytological specimen; National network genomic medicine

Mesh:

Year:  2022        PMID: 35925269     DOI: 10.1007/s00108-022-01365-1

Source DB:  PubMed          Journal:  Inn Med (Heidelb)        ISSN: 2731-7080


  11 in total

1.  Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.

Authors:  Si Kei Lou; Hyang Mi Ko; Tomonari Kinoshita; Scott MacDonald; Jessica Weiss; Katarzyna Czarnecka-Kujawa; Scott L Boerner; Kazuhiro Yasufuku; Ming-Sound Tsao; Joerg Schwock
Journal:  Acta Cytol       Date:  2020-06-29       Impact factor: 2.319

2.  A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases.

Authors:  Lisa M Rooper; Syed Z Ali; Matthew T Olson
Journal:  Cancer Cytopathol       Date:  2014-07-24       Impact factor: 5.284

Review 3.  [The national Network Genomic Medicine (nNGM) : Model for innovative diagnostics and therapy of lung cancer within a public healthcare system].

Authors:  R Büttner; J Wolf; A Kron
Journal:  Pathologe       Date:  2019-05       Impact factor: 1.011

4.  Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Authors:  Yasushi Yatabe; Sanja Dacic; Alain C Borczuk; Arne Warth; Prudence A Russell; Sylvie Lantuejoul; Mary Beth Beasley; Erik Thunnissen; Giuseppe Pelosi; Natasha Rekhtman; Lukas Bubendorf; Mari Mino-Kenudson; Akihiko Yoshida; Kim R Geisinger; Masayuki Noguchi; Lucian R Chirieac; Johan Bolting; Jin-Haeng Chung; Teh-Ying Chou; Gang Chen; Claudia Poleri; Fernando Lopez-Rios; Mauro Papotti; Lynette M Sholl; Anja C Roden; William D Travis; Fred R Hirsch; Keith M Kerr; Ming-Sound Tsao; Andrew G Nicholson; Ignacio Wistuba; Andre L Moreira
Journal:  J Thorac Oncol       Date:  2018-12-18       Impact factor: 15.609

5.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

6.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

7.  Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.

Authors:  Andrea Hernandez; Tamar C Brandler; Fei Chen; Fang Zhou; Yuhe Xia; Judy Zhong; Andre L Moreira; Anthony Simms; Wei Sun; Xiao Jun Wei; Aylin Simsir
Journal:  Am J Clin Pathol       Date:  2020-09-08       Impact factor: 2.493

Review 8.  [Cytology of body cavity fluids - established methods and new developments].

Authors:  Marianne Engels
Journal:  Pathologe       Date:  2022-01-07       Impact factor: 1.011

9.  Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

Authors:  M Janning; J Süptitz; C Albers-Leischner; P Delpy; A Tufman; J-L Velthaus-Rusik; M Reck; A Jung; D Kauffmann-Guerrero; I Bonzheim; S Brändlein; H-D Hummel; M Wiesweg; H-U Schildhaus; J A Stratmann; M Sebastian; J Alt; J Buth; I Esposito; J Berger; L Tögel; F C Saalfeld; M Wermke; S Merkelbach-Bruse; A M Hillmer; F Klauschen; C Bokemeyer; R Buettner; J Wolf; S Loges
Journal:  Ann Oncol       Date:  2022-03-06       Impact factor: 32.976

10.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Authors:  Fabrice Barlesi; Julien Mazieres; Jean-Philippe Merlio; Didier Debieuvre; Jean Mosser; Hervé Lena; L'Houcine Ouafik; Benjamin Besse; Isabelle Rouquette; Virginie Westeel; Fabienne Escande; Isabelle Monnet; Antoinette Lemoine; Rémi Veillon; Hélène Blons; Clarisse Audigier-Valette; Pierre-Paul Bringuier; Régine Lamy; Michèle Beau-Faller; Jean-Louis Pujol; Jean-Christophe Sabourin; Frédérique Penault-Llorca; Marc G Denis; Sylvie Lantuejoul; Franck Morin; Quân Tran; Pascale Missy; Alexandra Langlais; Bernard Milleron; Jacques Cadranel; Jean-Charles Soria; Gérard Zalcman
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.